11:15 AM EDT, 06/10/2024 (MT Newswires) -- Arcus Biosciences ( RCUS ) said Monday it completed the patient enrollment in a phase 3 trial of an experimental combination therapy of domvanalimab, zimberelimab and chemotherapy for people with upper gastrointestinal adenocarcinoma.

About 1,050 participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma have been enrolled for the trial, it said.

The primary endpoints of the study are overall survival in PD-L1-high tumors and in the intent-to-treat population, while secondary endpoints include progression-free survival, objective response rate and duration of response, Arcus said.

The study is being undertaken in collaboration with Gilead Sciences ( GILD ) .

Arcus said data from the phase 2 trial showed that patients treated with the two investigational antibodies - domvanalimab and zimberelimab - in combination with chemotherapy had a median progression-free survival of 12.9 months. That exceeds the historical benchmarks for zimberelimab plus chemotherapy alone, it said.

The domvanalimab-containing regimen demonstrated sustained improvement across efficacy measures and was generally well tolerated in the phase 2 trial, it said.

Price: 15.79, Change: +0.29, Percent Change: +1.84